Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer;Chirurgie de fermeture et chimiothérapie intra- péritonéale dans les cancers de l'ovaire de stade avancé ou en récidive

Gynecologie Obstetrique et Fertilite

Volumn 32, Issue 5, 2004, Pages 391-397

  Plaisant, N ^a   Quenet, F ^a   Fabbro, M ^a   Gourgou, S ^a   Gutowski, M ^a   Saint Aubert, B ^a   Rouanet, P ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Cancer de l'ovaire; Chemotherapy; Chimioth rapie; Chirurgie de fermeture; Ovarian cancer; Secondary debulking surgery

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EVALUATION; FOLLOW UP; HOSPITALIZATION; HUMAN; MINIMAL RESIDUAL DISEASE; MORTALITY; OVARY CANCER; REVIEW; SURVIVAL RATE; TREATMENT INDICATION;

EID: 2942638073     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2004.03.004     Document Type: Article

References (39)

1. Petterson F., Creasman W., Shepard J., et al. Annual report of the results of treatment in gynecological cancer. Annual Report. 1995;. Editorial Office, Radiumhemmet
2. Marsoni S., Torri V., Valsecchi M.G., et al. Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer. 62:(3):1990;444-450. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)
3. Omura G.A., Brady M.F., Homesley H.D., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 9:1991;1138-1150
4. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 42:1975;101-104
5. Alberts D.S., Dahlberg S., Green S.J., et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 71:(2 Suppl):1993;618-627
6. Ansell S.M., Rapoport B.L., Falkson G., et al. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol. 50:1993;215-220
7. Levin L., Lund B., Heintz A.P. Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol. 4:(Suppl 4):1993;23-29
8. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 170:1994;974-979. discussion 979-80
9. Dauplat J., Le Bouëdec G., Pomel C., et al. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol. 19:2000;42-48
10. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20:2002;1248-1259
11. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69:1998;103-108
12. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6
13. Stiff P.J., Bayer R., Kerger C., et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 15:1997;1309-1317
14. Copeland L.J., Gershenson D.M. Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet Gynecol. 68:1986;873-874
15. Podratz K.C., Schray M.F., Wieand H.S., et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol. 31:(1):1988;9-24
16. Markman M., Rowinsky E., Hakes T., et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 10:1992;1485-1491
17. Francis P., Rowinsky E., Schneider J., et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol. 13:(12):1995;2961-2967
18. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955
19. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 19:2001;1001-1007
20. Armstrong D., Bundy B., Baergen R., et al. Randomized phase III study of intraveinous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 172). Pro Am Soc Clin Oncol. 21:2002;201a. (Abstr 803)
21. Neijt J.P., Ten Bokkel Huinink W.W., Van Der Burg N.E., et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer. 27:(11):1991;1367-1372
22. Venesmaa P. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol. 84:1994;8-11
23. Michel G., Zarca D., Castaigne D., et al. Secondary cytoreductive surgery in ovarian cancer. Eur. J. Surg. Oncol. 15:1989;201-204
24. Hoskins W.J., Rubin S.C. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol. 18:1991;213-221
25. Griffiths C.T., Parker L.M., Lee S., et al. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer. 12:(4):2002;323-331
26. Bristow R.E., Lagasse L.D., Karlan B.Y. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer. 78:1996;2049-2062
27. Van Der Burg M.E., Van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the european organization for research and treatment of cancer. N Engl J Med. 332:1995;629-634
28. AOCTG. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. M. 303:1991;884-893
29. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol. 55:1994;S91-S96
30. Williams L., Brunetto V.L., Yordan E., et al. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 66:1997;171-178
31. Howell S.B., Pfeifle C.L., Wung W.E., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 97:(6):1982;845-851
32. Ozols R.F., Locker G.Y., Doroshow J.H., et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39:1979;3209-3214
33. Los G., Mutsaers P.H., Van Der Vijgh W.J., et al. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49:(12):1989;3380-3384
34. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 18:(3):1991;248-254
35. Markman M., Francis P., Rowinsky E., Hoskins W. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? Semin Oncol. 22:(3 Suppl 6):1995;84-87
36. McGuire W.P. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol. 51:1993;78-85
37. Markman M., Brady M.F., Spirtos N.M., et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 16:1998;2620-2624
38. Hofstra L.S., Bos A.M., de Vries E.G., et al. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol. 85:2002;517-523
39. Rothenberg M., Liu P., Wilczynski S., et al. Exellent two-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: a SWOG-ECOG-NCIC study (S9619). Proc Am Soc Clin Oncol. 2002;. Abst 809